


PHARMACEUTICAL 2020




GALECTIN THERAPEUTICS INC Rank 31 of 358





PHARMACEUTICAL 2020





The relative strengths and weaknesses of GALECTIN THERAPEUTICS INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of GALECTIN THERAPEUTICS INC compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 110% points. The greatest weakness of GALECTIN THERAPEUTICS INC is the variable Other Revenues, reducing the Economic Capital Ratio by 19% points.

The company's Economic Capital Ratio, given in the ranking table, is 254%, being 217% points above the market average of 36%.

Input Variable	Value in 1000 USD
Assets, Current	48,209
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	2,820
Liabilities, Non-Current	52
Other Assets	258
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	144
Other Revenues	0
Property and Equipment	0
Research and Development	7,467
Selling, General and Administrative Expense	5,971

Output Variable	Value in 1000 USD
Assets	48,467
Liabilities	2,872
Expenses	13,438
Revenues	0
Stockholders Equity	45,595
Net Income	-13,294
Comprehensive Net Income	-13,294
Economic Capital Ratio	254%

